Octreotide acetate

SKU: orb1941015

Description

An octapeptide that mimics natural somatostatin pharmacologically, that is 200 times more potent than somatostatin; has also been shown to produce analgesic effects, most probably acting as a partial agonist at the mu opioid receptor.(In Vivo):Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated.

Research Area

Pharmacology & Drug Discovery

Images & Validation

−

Key Properties

−

CAS Number	79517-01-4
MW	1079.291
Purity	>98% (HPLC)
Formula	C₅₁H₇₀N₁₀O₁₂S₂
SMILES	CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O
Target	Somatostatin Receptor
Solubility	DMSO: ≥ 29 mg/mL

Bioactivity

−

In Vivo

Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated.

Storage & Handling

−

Storage	Storage temperature: -20°C. Stability: ≥ 2 years
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

SMS-201995

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Quick Database Links

Gene Symbol

Somatostatin Receptor

Protocol Information

Find More Protocols

Purity:	≥95%
CAS Number:	79517-01-4
MW:	1139.36
Formula:	C₄₉H₆₆N₁₀O₁₀S₂ 2C₂H₄O₂

Purity:	> 95%
MW:	1019.2
Source:	Synthetic

Purity:	99.57% (May vary between batches)
MW:	1079.3